<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-03844107</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-03T15:25:21+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Blocking the IL-23/Th17 pathway ameliorates myasthenia gravis symptoms in autoimmune myasthenia gravis mouse model</title>
            <author role="aut">
              <persName>
                <forename type="first">Jose Adolfo</forename>
                <surname>Villegas</surname>
              </persName>
              <idno type="halauthorid">1708510-0</idno>
              <affiliation ref="#struct-1053657"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Sonia</forename>
                <surname>Berrih-Aknin</surname>
              </persName>
              <email type="md5">e024bff172993cdcaa8fdc4122e561ab</email>
              <email type="domain">upmc.fr</email>
              <idno type="idhal" notation="numeric">963984</idno>
              <idno type="halauthorid" notation="string">227608-963984</idno>
              <affiliation ref="#struct-1053657"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Rozen</forename>
                <surname>Le Panse</surname>
              </persName>
              <email type="md5">a29e1ce10f256f5a985fc5d893c0bf49</email>
              <email type="domain">upmc.fr</email>
              <idno type="idhal" notation="string">rozen-le-panse</idno>
              <idno type="idhal" notation="numeric">741448</idno>
              <idno type="halauthorid" notation="string">30148-741448</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-7522-5974</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/158510186</idno>
              <affiliation ref="#struct-1053657"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Nadine</forename>
                <surname>Dragin</surname>
              </persName>
              <email type="md5">adbf4a26e4d41687c98b02ee76e98a90</email>
              <email type="domain">upmc.fr</email>
              <idno type="idhal" notation="string">nadine-dragin</idno>
              <idno type="idhal" notation="numeric">1180740</idno>
              <idno type="halauthorid" notation="string">1024636-1180740</idno>
              <affiliation ref="#struct-1053657"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Nadine</forename>
                <surname>Dragin</surname>
              </persName>
              <email type="md5">adbf4a26e4d41687c98b02ee76e98a90</email>
              <email type="domain">upmc.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2022-11-15 13:50:53</date>
              <date type="whenModified">2025-08-12 17:09:40</date>
              <date type="whenReleased">2022-11-18 11:46:20</date>
              <date type="whenProduced">2021-05-28</date>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="735910">
                <persName>
                  <forename>Nadine</forename>
                  <surname>Dragin</surname>
                </persName>
                <email type="md5">adbf4a26e4d41687c98b02ee76e98a90</email>
                <email type="domain">upmc.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-03844107</idno>
            <idno type="halUri">https://hal.science/hal-03844107</idno>
            <idno type="halBibtex">villegas:hal-03844107</idno>
            <idno type="halRefHtml">&lt;i&gt;12th international congress on autoimmunity&lt;/i&gt;, May 2021, virtual, France</idno>
            <idno type="halRef">12th international congress on autoimmunity, May 2021, virtual, France</idno>
            <availability status="restricted"/>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="U974" corresp="SORBONNE-UNIVERSITE">CRM - Centre de recherche en myologie - U974</idno>
            <idno type="stamp" n="SORBONNE-UNIVERSITE">Sorbonne Université</idno>
            <idno type="stamp" n="SORBONNE-UNIV" corresp="SORBONNE-UNIVERSITE">Sorbonne Université 01/01/2018</idno>
            <idno type="stamp" n="SU-MEDECINE" corresp="SORBONNE-UNIVERSITE">Faculté de Santé de Sorbonne Université</idno>
            <idno type="stamp" n="ALLIANCE-SU"> Alliance Sorbonne Université</idno>
            <idno type="stamp" n="U974-E7" corresp="U974">Myasthenia Gravis: étiologie, physiopathologie &amp; approches thérapeutiques</idno>
            <idno type="stamp" n="SUPRA_-SVE6">SVE6 - Maladies humaines</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="invited" n="0">No</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
            <note type="proceedings" n="0">No</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Blocking the IL-23/Th17 pathway ameliorates myasthenia gravis symptoms in autoimmune myasthenia gravis mouse model</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Jose Adolfo</forename>
                    <surname>Villegas</surname>
                  </persName>
                  <idno type="halauthorid">1708510-0</idno>
                  <affiliation ref="#struct-1053657"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Sonia</forename>
                    <surname>Berrih-Aknin</surname>
                  </persName>
                  <email type="md5">e024bff172993cdcaa8fdc4122e561ab</email>
                  <email type="domain">upmc.fr</email>
                  <idno type="idhal" notation="numeric">963984</idno>
                  <idno type="halauthorid" notation="string">227608-963984</idno>
                  <affiliation ref="#struct-1053657"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Rozen</forename>
                    <surname>Le Panse</surname>
                  </persName>
                  <email type="md5">a29e1ce10f256f5a985fc5d893c0bf49</email>
                  <email type="domain">upmc.fr</email>
                  <idno type="idhal" notation="string">rozen-le-panse</idno>
                  <idno type="idhal" notation="numeric">741448</idno>
                  <idno type="halauthorid" notation="string">30148-741448</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-7522-5974</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/158510186</idno>
                  <affiliation ref="#struct-1053657"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Nadine</forename>
                    <surname>Dragin</surname>
                  </persName>
                  <email type="md5">adbf4a26e4d41687c98b02ee76e98a90</email>
                  <email type="domain">upmc.fr</email>
                  <idno type="idhal" notation="string">nadine-dragin</idno>
                  <idno type="idhal" notation="numeric">1180740</idno>
                  <idno type="halauthorid" notation="string">1024636-1180740</idno>
                  <affiliation ref="#struct-1053657"/>
                </author>
              </analytic>
              <monogr>
                <meeting>
                  <title>12th international congress on autoimmunity</title>
                  <date type="start">2021-05-28</date>
                  <settlement>virtual</settlement>
                  <country key="FR">France</country>
                </meeting>
                <imprint/>
              </monogr>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="sdv.bc">Life Sciences [q-bio]/Cellular Biology</classCode>
              <classCode scheme="halTypology" n="COMM">Conference papers</classCode>
              <classCode scheme="halOldTypology" n="COMM">Conference papers</classCode>
              <classCode scheme="halTreeTypology" n="COMM">Conference papers</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Background and aimsAutoimmune myasthenia gravis (MG) is caused by autoantibodies directed against the acetylcholine receptor AChR). In MG, the thymus is the effector tissue characterized by a chronic inflammation, defective regulatory T-cells and ectopic germinal centers (eGCs) (Berrih-Aknin 2014). A crosstalk between Th17 cells and thymic epithelial cells, mediated by IL-23 and IL-17, sustains thymic events supporting antibody production by B-cells found in eGCs (Villegas et al. 2019).We analyzed the effect of blocking the IL-23/Th17 axis, on the thymus and MG clinical course in a MG preclinical mouse model. Methods Immune-deficient NSG mice were engrafted with AChR+ MG thymic biopsies (NSG-MG). The NSG-MG model recapitulates MG symptoms and development (Sudres et al. 2017). Twenty five days after engraftment, mice were treated with a monoclonal anti human IL-23 antibody. We assessed the treatment effects on the engrafted thymic biopsies, muscle homeostasis and von MG global clinical score.ResultsThe treatment limited or stopped the activation of inflammatory T-cells (CD4+CCR6+ CCR4+ T- cells) in the thymus and the periphery. In addition, a decreased thymic expression of protein involved in eGC stabilization was observed. More, increased muscle regeneration gene expression and significant muscular improvements were observed and correlated with amelioration of clinical symptoms and global disease score.ConclusionAltogether these data suggest that an anti-IL-23 therapy could be beneficial in MG by acting on the thymic inflammatory state and on muscle physiology. The inhibition of IL-23 activates transduction pathways involved in antibody production and in muscle regeneration process favoring then disease amelioration.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-1053657" status="VALID">
          <idno type="IdRef">240715225</idno>
          <idno type="RNSR">200616450J</idno>
          <orgName>Centre de recherche en Myologie – U974 SU-INSERM</orgName>
          <date type="start">2018-01-01</date>
          <desc>
            <address>
              <addrLine>Faculté de Médecine Sorbonne UniversitéSite Pitié Salpêtrière105 boulevard de l’Hôpital  75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://recherche-myologie.fr/</ref>
          </desc>
          <listRelation>
            <relation name="U974" active="#struct-303623" type="direct"/>
            <relation name="UMRS_974" active="#struct-413221" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-413221" status="VALID">
          <idno type="IdRef">221333754</idno>
          <idno type="ROR">https://ror.org/02en5vm52</idno>
          <orgName>Sorbonne Université</orgName>
          <orgName type="acronym">SU</orgName>
          <date type="start">2018-01-01</date>
          <desc>
            <address>
              <addrLine>21 rue de l’École de médecine - 75006 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.sorbonne-universite.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>